Clinical Trials Regulation (CTR)
The EU Clinical Trials Regulation, which replaced Directive 2001/20/EC and harmonised the assessment and supervision of clinical trials across the EU/EEA through a single application submitted via the Clinical Trials Information System (CTIS). It introduces a coordinated assessment led by a Reporting Member State and increased transparency of trial information.
What this does not cover
stated in the document's own scope- Covers clinical trials of medicinal products for human use; clinical investigations of medical devices fall under the Medical Device Regulation (EU) 2017/745.
- Governs the trial authorisation and conduct, not the marketing authorisation of the finished medicine, which follows a separate EU pathway.
- Sets the regulatory framework, with the detailed GCP methodology supplied by ICH E6 rather than the regulation text itself.
- Applies to interventional clinical trials, not to low-intervention or purely observational studies beyond its defined scope.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Regulation (EU) 536/2014, the Clinical Trials Regulation (CTR), governs the authorisation and conduct of clinical trials on medicinal products for human use across the EU and EEA. It replaced the earlier Clinical Trials Directive with a single, harmonised regulation and a single entry point: sponsors submit one application through the Clinical Trials Information System (CTIS), and Member States carry out a coordinated assessment led by a Reporting Member State. The regulation covers the application and assessment procedure, the conduct of the trial, safety reporting, the roles of sponsor and investigator, informed consent, and a transparency regime that makes much trial information public.
Scope & applicability
Interventional clinical trials of medicinal products conducted in the EU/EEA. Since 31 January 2023 all new trials must be submitted under the CTR via CTIS; the transition of legacy Directive trials completed by 31 January 2025.
Legal basis & how it acquires force
The CTR is a Regulation, so it applies directly and uniformly in every Member State without national transposition — the key difference from the Directive it replaced, whose national implementations had diverged. It entered into force in 2014 but its application was tied to the CTIS portal becoming operational; it therefore became applicable on 31 January 2022, repealing Directive 2001/20/EC subject to a transition period for trials already running under the old regime. Its GCP expectations are met through ICH E6, adopted in the EU as a scientific guideline.
Document structure
| Part | Covers |
|---|---|
| Authorisation procedure | The single dossier, Part I and Part II assessment, and the Reporting Member State mechanism |
| Conduct of the trial | Sponsor and investigator obligations, informed consent, and protection of subjects |
| Safety reporting | Recording and reporting of adverse events, SUSARs, and annual safety reports |
| Manufacture and labelling of IMPs | Requirements for investigational and auxiliary medicinal products and their labelling |
| Transparency and CTIS | The EU database/portal, public availability of trial data, and deferral rules |
| Supervision and penalties | Member-State supervision, inspections, corrective measures, and penalties |
Key requirements
- Submit a single application via CTIS for authorisation across all concerned Member States
- Comply with the coordinated assessment timelines led by the Reporting Member State
- Report SUSARs and submit annual safety reports as required
- Meet CTIS transparency and document-publication obligations (with limited deferrals)
Implementation tips
- Assign clear CTIS role management (sponsor administrators) before the first submission
- Build a transparency plan mapping which documents can be deferred and for how long
Revision notes
Entered into application 31 January 2022, replacing Directive 2001/20/EC. Mandatory for new trials from 31 January 2023; legacy trials transitioned by 31 January 2025.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The CTR implements the principles of Good Clinical Practice harmonised in ICH E6, which the EU has adopted as a scientific guideline, and its safety-reporting rules build on the ICH E2A definitions of serious and unexpected reactions. It is the EU counterpart to the US clinical-trial framework under 21 CFR Parts 50, 56 and 312, and it operates alongside the EU GMP requirements for investigational medicinal products in Annex 13.
Regulation (EU) 536/2014: frequently asked questions
Quick answers to common questions about Regulation (EU) 536/2014.
What did Regulation (EU) 536/2014 replace?
It replaced Directive 2001/20/EC, the earlier Clinical Trials Directive. Because a Regulation applies directly in every Member State, the CTR removed the divergence that had arisen from separate national implementations of the Directive.
When did the Clinical Trials Regulation become applicable?
The CTR became applicable on 31 January 2022, once the Clinical Trials Information System (CTIS) was operational. A transition period allowed trials already authorised under the old Directive to migrate to the new framework.
What is CTIS under the CTR?
The Clinical Trials Information System is the single EU portal and database through which sponsors submit and manage trial applications and through which much trial information is made public. It is the operational backbone of the coordinated assessment the regulation introduced.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.